Loading…
Steatotic liver disease is the most important somatic determinant of quality of life in patients with obesity: A cross‐sectional study
Background and Aims Patients with metabolic dysfunction‐associated steatotic liver disease (MASLD) are often comorbid and stigmatized. This can negatively affect quality of life (QOL). Other studies have primarily used the Chronic Liver Disease Questionnaire (CLDQ), which focuses on liver‐related sy...
Saved in:
| Published in: | Liver international 2024-01, Vol.44 (1), p.191-201 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3881-92cfe399c3198475bf820e5ce4906b5738bdbcb62c6f1c3b0b98a8e2368f9dce3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3881-92cfe399c3198475bf820e5ce4906b5738bdbcb62c6f1c3b0b98a8e2368f9dce3 |
| container_end_page | 201 |
| container_issue | 1 |
| container_start_page | 191 |
| container_title | Liver international |
| container_volume | 44 |
| creator | Wernberg, Charlotte Wilhelmina Kjer, Mads Fallesen Grønkjær, Lea Ladegaard Jacobsen, Birgitte Gade Lauridsen, Mette Munk |
| description | Background and Aims
Patients with metabolic dysfunction‐associated steatotic liver disease (MASLD) are often comorbid and stigmatized. This can negatively affect quality of life (QOL). Other studies have primarily used the Chronic Liver Disease Questionnaire (CLDQ), which focuses on liver‐related symptoms, to characterize QOL, but most MASLD patients have only mild liver disease, and CLDQ might overlook QOL issues pertaining to them. We aimed to determine the impact of metabolic dysfunction‐associated steatohepatitis (MASH) on QOL in obese patients using a 136‐item generic QOL questionnaire.
Methods
We included participants with BMI ≥ 35 kg/m2 who all fully answered the sickness impact profile (SIP, range 0–100, normal = 3.4, 100 = worst) and had a liver biopsy to diagnose MASLD. Sociodemographics, comorbidity and biometric data were obtained from all participants.
Results
Of 176 (mean age 45.9 years, 70% female, 12.6 years of education), 132 had no‐MASH and 44 MASH. On stepwise multivariable regression analysis, divorce (p = .011), unemployment (p |
| doi_str_mv | 10.1111/liv.15761 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2884677116</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2884677116</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3881-92cfe399c3198475bf820e5ce4906b5738bdbcb62c6f1c3b0b98a8e2368f9dce3</originalsourceid><addsrcrecordid>eNp10c1KJDEQB_AgLuq6HnwBCXjRw4xJpz8SbyJ-DAzsYXWvTZKuxkh3Z0yllbl59Ogz-iSbcVwPgrmkCL_8qaQI2edsytM66dzjlBdVyTfIDs8rORGZ4JufdSa2yU_Ee8a4UgXfItuiUiwvRb5DXv5E0NFHZ2lKgUAbh6ARqEMa74D2HiN1_cKHqIdI0fd6ZRuIEHo3rM58Sx9G3bm4XJWda9PlgS6SgyEifXLxjnoDmMApPaM2eMS351cEG50fdEcxjs3yF_nR6g5h72PfJbeXFzfn15P576vZ-dl8YoWUfKIy24JQygquZF4VppUZg8JCrlhpikpI0xhrysyWLbfCMKOklpCJUraqsSB2ydE6dxH8wwgY696hha7TA_gR60zKvKwqzstED7_Qez-G1HFSiolM5Xkhkjpeq_eHBWjrRXC9Dsuas3o1njp9bP0-nmQPPhJH00PzKf_PI4GTNXhyHSy_T6rns7_ryH9dAJzH</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2903294453</pqid></control><display><type>article</type><title>Steatotic liver disease is the most important somatic determinant of quality of life in patients with obesity: A cross‐sectional study</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Wernberg, Charlotte Wilhelmina ; Kjer, Mads Fallesen ; Grønkjær, Lea Ladegaard ; Jacobsen, Birgitte Gade ; Lauridsen, Mette Munk</creator><creatorcontrib>Wernberg, Charlotte Wilhelmina ; Kjer, Mads Fallesen ; Grønkjær, Lea Ladegaard ; Jacobsen, Birgitte Gade ; Lauridsen, Mette Munk</creatorcontrib><description>Background and Aims
Patients with metabolic dysfunction‐associated steatotic liver disease (MASLD) are often comorbid and stigmatized. This can negatively affect quality of life (QOL). Other studies have primarily used the Chronic Liver Disease Questionnaire (CLDQ), which focuses on liver‐related symptoms, to characterize QOL, but most MASLD patients have only mild liver disease, and CLDQ might overlook QOL issues pertaining to them. We aimed to determine the impact of metabolic dysfunction‐associated steatohepatitis (MASH) on QOL in obese patients using a 136‐item generic QOL questionnaire.
Methods
We included participants with BMI ≥ 35 kg/m2 who all fully answered the sickness impact profile (SIP, range 0–100, normal = 3.4, 100 = worst) and had a liver biopsy to diagnose MASLD. Sociodemographics, comorbidity and biometric data were obtained from all participants.
Results
Of 176 (mean age 45.9 years, 70% female, 12.6 years of education), 132 had no‐MASH and 44 MASH. On stepwise multivariable regression analysis, divorce (p = .011), unemployment (p < .003) and hepatic steatosis (p = .01) were associated with poor overall QOL. No other somatic comorbidity was associated. MASH patients more frequently than no‐MASH reported physical discomfort (48% vs. 30%, p = .04), inability to do daily activities (29% vs. 54%, p = .006) and attention problems (32% vs. 57%, p = .003).
Conclusion
MASLD severity was the only somatic determinant of QOL in patients with obesity in this cohort, and a large fraction reported debilitating symptoms. Patients and caregivers should consider the limitations this poses when planning interventions.</description><identifier>ISSN: 1478-3223</identifier><identifier>EISSN: 1478-3231</identifier><identifier>DOI: 10.1111/liv.15761</identifier><identifier>PMID: 37904634</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Biopsy ; Comorbidity ; Cross-Sectional Studies ; Fatty liver ; Fatty Liver - epidemiology ; Female ; Humans ; Liver ; Liver diseases ; Male ; Metabolism ; Middle Aged ; non‐alcoholic fatty liver disease ; Obesity ; Obesity - complications ; Obesity - epidemiology ; Quality of Life ; Questionnaires ; Regression analysis ; sickness impact profile ; Signs and symptoms ; Steatosis</subject><ispartof>Liver international, 2024-01, Vol.44 (1), p.191-201</ispartof><rights>2023 The Authors. published by John Wiley & Sons Ltd.</rights><rights>2023 The Authors. Liver International published by John Wiley & Sons Ltd.</rights><rights>2023. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3881-92cfe399c3198475bf820e5ce4906b5738bdbcb62c6f1c3b0b98a8e2368f9dce3</citedby><cites>FETCH-LOGICAL-c3881-92cfe399c3198475bf820e5ce4906b5738bdbcb62c6f1c3b0b98a8e2368f9dce3</cites><orcidid>0000-0001-8964-0650 ; 0000-0003-0586-8549 ; 0000-0001-5754-8235</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37904634$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wernberg, Charlotte Wilhelmina</creatorcontrib><creatorcontrib>Kjer, Mads Fallesen</creatorcontrib><creatorcontrib>Grønkjær, Lea Ladegaard</creatorcontrib><creatorcontrib>Jacobsen, Birgitte Gade</creatorcontrib><creatorcontrib>Lauridsen, Mette Munk</creatorcontrib><title>Steatotic liver disease is the most important somatic determinant of quality of life in patients with obesity: A cross‐sectional study</title><title>Liver international</title><addtitle>Liver Int</addtitle><description>Background and Aims
Patients with metabolic dysfunction‐associated steatotic liver disease (MASLD) are often comorbid and stigmatized. This can negatively affect quality of life (QOL). Other studies have primarily used the Chronic Liver Disease Questionnaire (CLDQ), which focuses on liver‐related symptoms, to characterize QOL, but most MASLD patients have only mild liver disease, and CLDQ might overlook QOL issues pertaining to them. We aimed to determine the impact of metabolic dysfunction‐associated steatohepatitis (MASH) on QOL in obese patients using a 136‐item generic QOL questionnaire.
Methods
We included participants with BMI ≥ 35 kg/m2 who all fully answered the sickness impact profile (SIP, range 0–100, normal = 3.4, 100 = worst) and had a liver biopsy to diagnose MASLD. Sociodemographics, comorbidity and biometric data were obtained from all participants.
Results
Of 176 (mean age 45.9 years, 70% female, 12.6 years of education), 132 had no‐MASH and 44 MASH. On stepwise multivariable regression analysis, divorce (p = .011), unemployment (p < .003) and hepatic steatosis (p = .01) were associated with poor overall QOL. No other somatic comorbidity was associated. MASH patients more frequently than no‐MASH reported physical discomfort (48% vs. 30%, p = .04), inability to do daily activities (29% vs. 54%, p = .006) and attention problems (32% vs. 57%, p = .003).
Conclusion
MASLD severity was the only somatic determinant of QOL in patients with obesity in this cohort, and a large fraction reported debilitating symptoms. Patients and caregivers should consider the limitations this poses when planning interventions.</description><subject>Biopsy</subject><subject>Comorbidity</subject><subject>Cross-Sectional Studies</subject><subject>Fatty liver</subject><subject>Fatty Liver - epidemiology</subject><subject>Female</subject><subject>Humans</subject><subject>Liver</subject><subject>Liver diseases</subject><subject>Male</subject><subject>Metabolism</subject><subject>Middle Aged</subject><subject>non‐alcoholic fatty liver disease</subject><subject>Obesity</subject><subject>Obesity - complications</subject><subject>Obesity - epidemiology</subject><subject>Quality of Life</subject><subject>Questionnaires</subject><subject>Regression analysis</subject><subject>sickness impact profile</subject><subject>Signs and symptoms</subject><subject>Steatosis</subject><issn>1478-3223</issn><issn>1478-3231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><recordid>eNp10c1KJDEQB_AgLuq6HnwBCXjRw4xJpz8SbyJ-DAzsYXWvTZKuxkh3Z0yllbl59Ogz-iSbcVwPgrmkCL_8qaQI2edsytM66dzjlBdVyTfIDs8rORGZ4JufdSa2yU_Ee8a4UgXfItuiUiwvRb5DXv5E0NFHZ2lKgUAbh6ARqEMa74D2HiN1_cKHqIdI0fd6ZRuIEHo3rM58Sx9G3bm4XJWda9PlgS6SgyEifXLxjnoDmMApPaM2eMS351cEG50fdEcxjs3yF_nR6g5h72PfJbeXFzfn15P576vZ-dl8YoWUfKIy24JQygquZF4VppUZg8JCrlhpikpI0xhrysyWLbfCMKOklpCJUraqsSB2ydE6dxH8wwgY696hha7TA_gR60zKvKwqzstED7_Qez-G1HFSiolM5Xkhkjpeq_eHBWjrRXC9Dsuas3o1njp9bP0-nmQPPhJH00PzKf_PI4GTNXhyHSy_T6rns7_ryH9dAJzH</recordid><startdate>202401</startdate><enddate>202401</enddate><creator>Wernberg, Charlotte Wilhelmina</creator><creator>Kjer, Mads Fallesen</creator><creator>Grønkjær, Lea Ladegaard</creator><creator>Jacobsen, Birgitte Gade</creator><creator>Lauridsen, Mette Munk</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8964-0650</orcidid><orcidid>https://orcid.org/0000-0003-0586-8549</orcidid><orcidid>https://orcid.org/0000-0001-5754-8235</orcidid></search><sort><creationdate>202401</creationdate><title>Steatotic liver disease is the most important somatic determinant of quality of life in patients with obesity: A cross‐sectional study</title><author>Wernberg, Charlotte Wilhelmina ; Kjer, Mads Fallesen ; Grønkjær, Lea Ladegaard ; Jacobsen, Birgitte Gade ; Lauridsen, Mette Munk</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3881-92cfe399c3198475bf820e5ce4906b5738bdbcb62c6f1c3b0b98a8e2368f9dce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Biopsy</topic><topic>Comorbidity</topic><topic>Cross-Sectional Studies</topic><topic>Fatty liver</topic><topic>Fatty Liver - epidemiology</topic><topic>Female</topic><topic>Humans</topic><topic>Liver</topic><topic>Liver diseases</topic><topic>Male</topic><topic>Metabolism</topic><topic>Middle Aged</topic><topic>non‐alcoholic fatty liver disease</topic><topic>Obesity</topic><topic>Obesity - complications</topic><topic>Obesity - epidemiology</topic><topic>Quality of Life</topic><topic>Questionnaires</topic><topic>Regression analysis</topic><topic>sickness impact profile</topic><topic>Signs and symptoms</topic><topic>Steatosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wernberg, Charlotte Wilhelmina</creatorcontrib><creatorcontrib>Kjer, Mads Fallesen</creatorcontrib><creatorcontrib>Grønkjær, Lea Ladegaard</creatorcontrib><creatorcontrib>Jacobsen, Birgitte Gade</creatorcontrib><creatorcontrib>Lauridsen, Mette Munk</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Wiley-Blackwell Open Access Backfiles</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Liver international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wernberg, Charlotte Wilhelmina</au><au>Kjer, Mads Fallesen</au><au>Grønkjær, Lea Ladegaard</au><au>Jacobsen, Birgitte Gade</au><au>Lauridsen, Mette Munk</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Steatotic liver disease is the most important somatic determinant of quality of life in patients with obesity: A cross‐sectional study</atitle><jtitle>Liver international</jtitle><addtitle>Liver Int</addtitle><date>2024-01</date><risdate>2024</risdate><volume>44</volume><issue>1</issue><spage>191</spage><epage>201</epage><pages>191-201</pages><issn>1478-3223</issn><eissn>1478-3231</eissn><abstract>Background and Aims
Patients with metabolic dysfunction‐associated steatotic liver disease (MASLD) are often comorbid and stigmatized. This can negatively affect quality of life (QOL). Other studies have primarily used the Chronic Liver Disease Questionnaire (CLDQ), which focuses on liver‐related symptoms, to characterize QOL, but most MASLD patients have only mild liver disease, and CLDQ might overlook QOL issues pertaining to them. We aimed to determine the impact of metabolic dysfunction‐associated steatohepatitis (MASH) on QOL in obese patients using a 136‐item generic QOL questionnaire.
Methods
We included participants with BMI ≥ 35 kg/m2 who all fully answered the sickness impact profile (SIP, range 0–100, normal = 3.4, 100 = worst) and had a liver biopsy to diagnose MASLD. Sociodemographics, comorbidity and biometric data were obtained from all participants.
Results
Of 176 (mean age 45.9 years, 70% female, 12.6 years of education), 132 had no‐MASH and 44 MASH. On stepwise multivariable regression analysis, divorce (p = .011), unemployment (p < .003) and hepatic steatosis (p = .01) were associated with poor overall QOL. No other somatic comorbidity was associated. MASH patients more frequently than no‐MASH reported physical discomfort (48% vs. 30%, p = .04), inability to do daily activities (29% vs. 54%, p = .006) and attention problems (32% vs. 57%, p = .003).
Conclusion
MASLD severity was the only somatic determinant of QOL in patients with obesity in this cohort, and a large fraction reported debilitating symptoms. Patients and caregivers should consider the limitations this poses when planning interventions.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>37904634</pmid><doi>10.1111/liv.15761</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-8964-0650</orcidid><orcidid>https://orcid.org/0000-0003-0586-8549</orcidid><orcidid>https://orcid.org/0000-0001-5754-8235</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1478-3223 |
| ispartof | Liver international, 2024-01, Vol.44 (1), p.191-201 |
| issn | 1478-3223 1478-3231 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2884677116 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Biopsy Comorbidity Cross-Sectional Studies Fatty liver Fatty Liver - epidemiology Female Humans Liver Liver diseases Male Metabolism Middle Aged non‐alcoholic fatty liver disease Obesity Obesity - complications Obesity - epidemiology Quality of Life Questionnaires Regression analysis sickness impact profile Signs and symptoms Steatosis |
| title | Steatotic liver disease is the most important somatic determinant of quality of life in patients with obesity: A cross‐sectional study |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T08%3A02%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Steatotic%20liver%20disease%20is%20the%20most%20important%20somatic%20determinant%20of%20quality%20of%20life%20in%20patients%20with%20obesity:%20A%20cross%E2%80%90sectional%20study&rft.jtitle=Liver%20international&rft.au=Wernberg,%20Charlotte%20Wilhelmina&rft.date=2024-01&rft.volume=44&rft.issue=1&rft.spage=191&rft.epage=201&rft.pages=191-201&rft.issn=1478-3223&rft.eissn=1478-3231&rft_id=info:doi/10.1111/liv.15761&rft_dat=%3Cproquest_cross%3E2884677116%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3881-92cfe399c3198475bf820e5ce4906b5738bdbcb62c6f1c3b0b98a8e2368f9dce3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2903294453&rft_id=info:pmid/37904634&rfr_iscdi=true |